Next Article in Journal
Underutilized but Sustainable: The Case for Fava Beans in the Iberian Peninsula
Previous Article in Journal
Serotonin, Kynurenine, and Indole Pathways of Tryptophan Metabolism in Humans in Health and Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 18
Issue 3
10.3390/nu18030508
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Genetic Variation in Response to the Mediterranean–DASH Intervention for Neurodegenerative Delay (MIND): A Randomized Controlled Trial

by
Marilyn C. Cornelis
1,* and
Lisa L. Barnes
2,3
1
Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
2
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
3
Rush Alzheimer’s Disease Center, Chicago, IL 60612, USA
*
Author to whom correspondence should be addressed.
Nutrients 2026, 18(3), 508; https://doi.org/10.3390/nu18030508
Submission received: 19 December 2025 / Revised: 15 January 2026 / Accepted: 20 January 2026 / Published: 2 February 2026
(This article belongs to the Section Nutrigenetics and Nutrigenomics)
Browse Figures
Versions Notes

Abstract

Background: The Mediterranean–DASH Intervention for Neurodegenerative Delay (MIND) study was a 3-year randomized controlled trial to test the effects of the MIND diet on cognitive decline in individuals at risk for Alzheimer’s dementia (AD). Here we examine whether genetic differences in (a) AD predisposition and (b) nutrient metabolism modify the effect of MIND on cognitive change. Methods: This secondary analysis included 494 trial participants of genetically inferred European ancestry with genetic data. Genetic scores (GS) were derived from prior genome-wide studies of AD and nutrient biomarkers. Linear regression and linear mixed models were used to examine the main effects of GS and interactions with diet assignment on cognition. An exploratory genome-wide interaction analysis was also performed. Results: We observed a statistically significant interaction (p = 0.002) between the COMT Val158Met variant and diet assignment for the 3-year change in perceptual speed. Met/Met (lower enzyme activity) carriers’ perceptual speed improved more on the MIND than the control diet, while no difference by diet was observed for Val carriers. Conclusions: Catechol-O-methyltransferase (COMT) metabolizes catecholamines as well as polyphenols unique to the MIND diet. Individuals with genetically impaired COMT activity may be especially responsive to the cognitive benefits of the MIND diet.

1. Introduction

The Mediterranean–DASH Intervention for Neurodegenerative Delay (MIND) diet is based on the most compelling evidence in the diet–dementia field [1,2]. The MIND diet emphasizes consuming green leafy vegetables, olive oil, berries, nuts, legumes, whole grains, seafood, poultry, wine, and limited intake of animal and high-saturated-fat foods (Table S1). Population studies suggest adherence to the diet may slow the rate of cognitive decline and decrease the risk of dementia [3]. The first and longest randomized controlled trial (RCT) of a calorie-restricted MIND diet on cognitive change reported no significant differences in cognitive change after 3 years compared to a calorie-restricted control diet. Both arms lost weight and presented with significant improvements in cognition, thus potentially emphasizing a key role of weight management in brain health [4]. The latter is also supported by results of two smaller and shorter RCTs of a calorie-restricted MIND diet [5,6].
The rate of age-associated cognitive decline varies among individuals, and this variation likely arises from a complex interplay of genetic and environmental factors. Prior studies have examined APOE ε4 and comprehensive AD genetic scores as potential modifiers of the MIND diet with cognitive outcomes, but findings have been mixed [4,7,8,9,10,11]. Genetic variation in the metabolism of constituents characteristic of the MIND diet may enhance or limit their efficacy, but has not been examined. For example, genetic variants have been identified for nutrient biomarkers that correlate with MIND foods such as vitamin K (greens), vitamin E (olive oil, nuts, greens), carotenoids (other vegetables), polyphenols (berries, olive oil), folate (beans, greens, other vegetables), and oleic and azelaic acid (olive oil) (Table S2), which might in turn modify anti-inflammatory, antioxidant, vascular or neural responses to MIND that benefit cognitive function [12]. The current study is a secondary analysis of the 3-year MIND RCT, which examines whether genetic differences in AD predisposition and nutrient metabolism modify the effect of the MIND diet on cognitive change. Considering the results of MIND RCTs and the role of insulin resistance and obesity in cognitive decline [13,14,15,16], genetic susceptibility to these disorders was also considered. A genome-wide analysis of the effect of MIND on cognitive change was explored to provide a data resource for other nutrition or genetic investigators.

2. Materials and Methods

2.1. The MIND Trial

The MIND trial design and results from the primary analysis have been published previously [4,17]. This 3-year RCT examined the effect of a calorie-restricted MIND diet compared to a calorie-restricted usual diet (control diet) on cognitive decline. The trial had two clinical sites: Chicago (Rush University) and Boston (Harvard University). Men and women aged 65+ years who were cognitively unimpaired, overweight, and had a family history of dementia and a suboptimal diet (MIND score ≤ 8 out of 14) were recruited. Those determined eligible completed a 3- to 4-week run-in to assess their likelihood of complying with trial interventions. Participants who successfully completed the run-in were invited back to complete a 2-day baseline visit. Measures of height, weight, and a fasting blood sample were collected, cognition tests were performed, and questionnaires were completed. All participants were randomly assigned in a 1:1 ratio to the MIND-diet group or the control-diet group, stratified by trial site, sex, and age. Both assigned diets had mild calorie restriction (250 kcal deficit/d) to achieve a weight loss of 3–5% by year 3. The MIND diet is detailed in Table S1. While the original MIND diet encourages up to 1 glass of wine per day, no wine recommendations were made for the trial. The control diet consisted of the usual diet. MIND-diet participants were supplied with mixed nuts (5 oz/week), extra virgin olive oil (14 tbsp/week), and blueberries (2.5 cups/week). Control-diet participants received USD 30 gift cards per week. All clinical measures, data collection, and biospecimen handling were performed by trained clinical staff. During the COVID-19 pandemic, in-person visits were halted for ~3 months, but dietary counseling by telephone continued. After stay-at-home orders were lifted, 24 participants in the MIND-diet group and 20 in the control-diet group declined to return for an in-person visit.
The trial followed the ethical standards of the 1964 Declaration of Helsinki and its later amendments and was approved by the institutional review boards at Rush University Medical Center, Harvard School of Public Health, and Brigham and Women’s Hospital. Participants were enrolled from January 2017 to April 2018; data collection ended in June 2021. A total of 604 participants were enrolled and randomized. All the participants provided written informed consent.

2.2. Cognitive Battery

The primary endpoint of the MIND trial was the change from baseline to year 3 in a global cognition score and four cognitive domain scores. A battery of 12 cognitive tests was administered during clinical visits at baseline, 6 months, 12 months, 24 months, and 36 months. Cognitive testing was conducted by research assistants who were certified in cognitive testing and blinded to diet assignments. Tests for episodic memory, semantic memory, perceptual speed, and executive function are listed in Table S3. The raw scores from each test were converted to z-scores, which were averaged across all tests to create the global cognition score and across component tests to create the four domain scores; higher scores indicate better cognitive performance. Participants who did not return for in-person visits in year 3 completed episodic and semantic memory tests by telephone.

2.3. Genetic Data and Calculation of Genetic Scores (GS)

Genotyping, imputation, and quality control (QC) procedures for the genetic data of trial participants have been described in detail previously [18]. Briefly, DNA was extracted from either whole blood or serum, and genotyping was performed using the Infinium Global Diversity Array. Established sample and SNP QC procedures were applied to the genotyping data, followed by imputation using the 1000 Genomes Phase 3 v5 reference panel. A total of 494 unrelated individuals of inferred European ancestry and 58 unrelated individuals of inferred African ancestry were included in the final imputed dataset. The current analysis is limited to the 494 participants of European ancestry to avoid population stratification, and since sample sizes of other ancestries were too small for meaningful analysis. All SNPs initially selected for genetic scores (GS) were genome-wide significant (p < 5 × 10−8, GSvitK the exception), biallelic and common (MAF > 1%) in GWAS of European ancestry. We then excluded SNPs poorly imputed (R2 < 0.8) in the MIND trial sample and that lacked high-quality proxies (1 SNP for folate and 1 SNP for IR). GS for AD (GSAD) was computed as described previously using 25 SNPs (excluding APOE SNPs, Table S4) [9,19,20]. GSAD uses the sum of the products of SNP risk alleles and their corresponding weights as GSAD = Σin log(ORij) × Gij for the ith individual, where log(ORij) = the log of the OR for the jth SNP, Gij = the number of risk alleles (0, 1, or 2) for the jth SNP, and n = 25 candidate SNPs. The score is rescaled according to the number of risk alleles (#SNPs×2) to facilitate interpretation. A higher GSAD corresponds to an elevated AD risk. GSAD-I and GSAD-C are subset scores of GSAD and include SNPs mapping to, respectively, the immune response (10 SNPs) and cholesterol metabolism (4 SNPs) pathways (Table S4). APOE was not included in the GSs because of its large effect size, and it was previously examined separately in the main MIND trial results [4]. The same scoring method (using beta coefficients in place of logOR if possible) was used to generate GS for vitamin K (phylloquinone, 4 SNPs, GSvitK), vitamin E (alpha + gamma tocopherols, 5 SNPs, GSvitE), beta-carotene (1 SNP, GSβcar), alpha-carotene (3 SNPs, GSαcar), folate (1 SNP, GSfolate), brain Fe (12 SNPs, GSFe), azelaic acid (1 SNP, GSazelaic) and oleic acid (1 SNP, GSoleic) using results of corresponding biomarker GWAS (Table S2). Finally, a GS for BMI (75 SNPs, GSBMI) [21] and insulin resistance (28 SNPs, GSIR) [22] was also derived.

2.4. Statistical Analysis

All statistical analyses were performed using the SAS v9.4 statistical package (SAS Institute, Cary, NC, USA) and PLINK 2.0.
Hypothesis testing: We first examined the main effects of GS (modeled additively/continuously) on baseline cognition and cognitive change independent of diet assignment using linear regression and linear mixed models, respectively. Linear regression models included terms for GS, age, sex, study site, specimen, and the top 10 PCs. Linear mixed models included terms for GS, age, sex, study site, DNA specimen, and the top 10 PCs as fixed effects; intercept and time (visit, slope) as random effects; and multiplicative terms between time and each model covariate. Mixed models included all available data, including those from participants with incomplete follow-up; missing data were not imputed and assumed to be missing at random. As per the original trial analyses, trajectories of cognition across time were nonlinear and thus time was modeled as an indicator variable for each visit. Within-person residuals were assumed to follow a first-order autoregressive model that was conditional on the random intercepts. The GS × time term estimated mean differences in rates of cognitive change with increasing GS. Participants with no follow-up visits (N = 13) contributed to the estimation of fixed effects and the overall mean but did not contribute to estimating within-person variance or random effects. Mean cognition at baseline and mean change in cognition from baseline by GS were computed using estimated marginal means. We then proceeded to test for GS × diet interactions on cognitive change by adding diet assignment and cross-product terms of diet × time, and GS × diet × time to mixed models; the latter providing an estimate of the interaction for cognitive change. Formal interaction testing was complemented by tabulating mean cognitive change from baseline stratified by diet assignment and GS tertiles (or genotype for GS composed of a single SNP). We tested 14 GS for interactions with diet on change in global cognition, and specific domains of episodic memory, executive function, perceptual speed, and semantic memory. A Bonferroni correction was used to account for 14 GS tested: p-values less than 0.004 (=0.05/14 tests) were considered statistically significant. We did not correct for the number of cognition measures since they were generally correlated. Nevertheless, we applied a post hoc false discovery rate (FDR) correction to evaluate the robustness of our interaction results. For significant interactions, we further examined whether results persisted when adjusting for weight change or if the interacting GS was associated with diet adherence or loss to follow-up. We also explored associations between GS and spot urine measures of tyrosol (corrected for creatinine) available in a subset of our analytical sample at baseline, 3 months, 12 months, 24 months, and 36 months [23]. We analyzed participants with baseline and at least one follow-up measure of tyrosol and excluded only two outlying data points (one from each diet arm at 12 months) that were over 19-fold higher than the sample mean. Linear mixed models, as described above for cognitive change, were also applied for urinary tyrosol change with additional adjustment for batch.
Hypothesis generating (exploratory): Two approaches to the genome-wide (GW) diet interaction analysis were performed. First, mixed effects models described above, but excluding GS and diet assignment, were used to estimate individual paths of change in cognition. Unlike our hypothesis testing approach described above, time was modeled linearly to avoid downstream modeling of multiple paths (per visit) per individual. Residuals, individual slopes, were extracted from these models and used as quantitative outcome phenotypes for GW interaction testing using linear regression models. Predictor variables included SNP, diet assignment, and SNP × diet assignment. The second approach used each participant’s change in cognition from baseline to 36 months as the outcome for GW interaction testing and further adjusting for covariates listed for mixed models described above. For individuals with missing test scores at 36 months (N = 31 for global, semantic, and episodic, 63 for perceptual, and 64 for executive), we carried forward their last test score. We considered results for SNPs with MAF > 1% and high imputation quality scores (R2 > 0.8), leaving 7,647,009 SNPs for analysis. We applied a genome-wide interaction significance threshold of p < 5 × 10−8 for either approach, but considered only results that were consistent across approaches as promising.

3. Results

Baseline characteristics of the MIND trial participants used in the current analysis are presented in Table 1. As expected, the self-identified race of our sample (selected on European ancestry) differed from the full trial sample.

3.1. Hypothesis Testing

None of the GS were significantly associated with baseline measures of cognition (p > 0.004). Nominal associations were observed between GSazelaic and executive (p = 0.04), GSBMI and global (p = 0.03), GSCOMT and executive (p = 0.03), and GSfolate and semantic (p = 0.02) (Table S5). Greater genetic susceptibility to higher blood azelaic acid, BMI, and blood folate was associated with better baseline performance on executive function, global cognition, and semantic memory tests, respectively. Higher genetically inferred COMT expression (GSCOMT, Val/Val) was associated with lower executive function.
In linear mixed models, none of the GS were significantly associated with changes in cognition after 3 years (p > 0.004). Higher genetically inferred blood azelaic acid (GSazelaic) nominally associated with less improvement in executive function (p = 0.009) (Figure S1, Table S6), while higher genetically inferred COMT expression (GSCOMT, Val/Val) was nominally associated with greater improvement in executive function (p = 0.02) (Figure 1, Table S6).
We observed a statistically significant GSCOMT × diet × time interaction (p = 0.002) for the 3-year change in perceptual speed, whereby Met/Met (lower COMT expression) carriers performed better on MIND (Figure 2A) than the control diet (Figure 2B and Table S7). From baseline through year 3, the estimated mean (95% CI) change in perceptual speed score was 0.18 (0.07, 0.30) standardized units in Met/Met carriers on the MIND diet and 0.03 (−0.13, 0.18) standardized units in Met/Met carriers on the control diet. Conversely, no difference in change in perceptual speed over time by diet was observed for Val carriers. This interaction was not significant (q value = 0.11) when applying an FDR threshold of 0.05. In post hoc analysis, the interaction persisted (p = 0.002) when models were further adjusted for weight change. GSCOMT was not associated with a change in MIND diet adherence overall or among the MIND diet arm specifically (p > 0.05). GSCOMT was also not associated with the number of follow-up visits (p > 0.05). Measures of urinary tyrosol (corrected for creatinine), a polyphenol and biomarker of olive oil intake, were available for 388 participants (172 MIND arm, 166 control arm) of our analytical sample. GSCOMT was not associated with baseline (i.e., pre-intervention) tyrosol (p > 0.05) or change in tyrosol after 3 years (p > 0.05). A nominal GSCOMT × diet × time interaction (p = 0.03) for the 3-year change in tyrosol was observed, but was not interpretable upon visualization (Figure S2). No evidence of interaction was observed when truncating outlying tyrosol measures to 4 SD of the mean (p > 0.05).

3.2. Hypothesis Generating

The union of two approaches to GW interaction testing yielded genome-wide signals for change in global cognition (1 locus), executive function (17 loci), perceptual speed (1 locus), and semantic memory (9 loci) (Table S8, https://prism.northwestern.edu/, Figures S3–S6). Index SNP allele frequencies ranged from 0.01 to 0.09; 16 were intronic, 11 were intergenic, while the remaining were in untranslated regions. Mean change in cognitive scores from baseline stratified by genotype and diet assignment confirmed that most interactions were driven by extreme scores among the very few heterozygotes and homozygote minor allele carriers (Table S9).

4. Discussion

In this secondary analysis of the 3-year MIND RCT, we examined whether genetic differences in AD predisposition and nutrient metabolism modify the effect of the MIND diet on cognitive change. We confirm our prior population studies showing that genetic differences in AD susceptibility do not modify the association between MIND adherence and cognitive decline [8,9]. To our knowledge, this is the first study to examine whether genetic differences in MIND-specific nutrient metabolism impact the effect of the MIND diet on cognition over time. Our primary findings pertain to a well-characterized COMT variant, which presented both main effects and interactions with diet assignment on cognition.
The MIND diet is rich in polyphenols due largely to the olive oil, berries, and other fruits and vegetables specified [24,25,26]. In the MIND diet trial, extra virgin olive oil and blueberries were provided to participants assigned to the MIND diet to promote adherence to the diet. Olive oil and blueberries are rich sources of hydroxytyrosol and anthocyanins, respectively, known for their antioxidant, anti-inflammatory, and neuroprotective properties [27,28]. COMT encodes catechol-O-methyltransferase, an enzyme that metabolizes catecholamines as well as polyphenols such as hydroxytyrosol, anthocyanins, and flavan-3-ols (i.e., catechins) [29]. Our GSCOMT includes one SNP (rs4680) resulting in a Val158Met substitution in COMT [30]. A progressive reduction in COMT protein and COMT enzymatic activity occurs in a Met dose–response manner, which results in higher synaptic dopamine [30,31,32,33,34]. Nominal associations were observed for GSCOMT with both baseline and 3-year change in executive function (independent of diet assignment). Our findings linking COMT rs4680 to executive function are consistent with prior studies [35,36] and key roles of the prefrontal cortex and dopamine in executive function [33,37]. Val/Val carriers had the lowest baseline score, but over 3 years, presented with the greatest score improvement. The lower baseline scores for Val/Val carriers might be more responsive to re-testing or weight loss effects (both diets), while test ceiling effects mask any additional improvement among Met carriers. In a small RCT, Val/Val carriers had lower memory scores than Met carriers at baseline but presented with greater improvements after 3 months of caloric restriction [38]. Methylation typically reduces the biological activity of a compound [29,39,40] and thus we hypothesized that Met/Met carriers (lower GSCOMT) may perform cognitively better on the MIND diet than the control diet compared to Val/Val carriers (higher GSCOMT). Indeed, we observed a statistically significant and novel GSCOMT × diet interaction for 3-year change in perceptual speed, whereby Met/Met performed better on the MIND diet than the control diet. No difference in change by diet was observed for Val carriers. The interpretation of the results is complicated by studies suggesting the main biological metabolite of hydroxytyrosol is the product of COMT: 3-O-methyl-hydroxytyrosol (also known as homovanillyl alcohol) [41,42,43]. In this scenario, higher COMT (Val/Val) activity would be preferred. Biomarkers serving as direct substrates or metabolites of COMT were not measured in the trial. Tyrosol is structurally related to hydroxytyrosol and is also present in olive oil, but is not a substrate/metabolite of COMT since it lacks the catechol structure [44]. However, it can be partially converted to hydroxytyrosol and thus could be a precursor [45]. Nevertheless, our analysis of urinary tyrosol in a subset of trial participants did not support our significant findings for COMT. Since COMT has multiple substrates and functions, deciphering the constituents of MIND driving the observed interaction warrants further study. Why this interaction was specific to perceptual speed (and not executive function) is also unclear. In a recent proteomic analysis of eight healthy diet patterns in the UK Biobank, COMT was significantly and inversely associated with all dietary patterns, but most strongly with MIND [46]. This suggests that MIND adherence may also modify the activity of COMT, but whether this association is causal is unknown.
Azelaic acid is a potential biomarker of olive oil, berry, and whole grain intake [47,48,49]. It is also a metabolic byproduct of Malassezia furfur, a yeast found on human skin, and is used topically in many skincare products [50]. Our GSazelaic contains one SNP in the intronic region of SLC17A1; the A allele associates with higher blood azelaic acid levels compared to the G allele in GWAS [51]. While only nominally significant, baseline executive function increased with each A allele, and after 3 years, participants homozygous for G (lowest performance at baseline) saw greater improvement in executive function; no interaction with diet assignment was observed. This pattern of results mirrors that of GSCOMT, and thus a similar interpretation holds. SLC17A1 is highly expressed in the kidney and functions in the transport of organic anions, in particular, urate [52]. Indeed, the A allele also associates with higher uric acid in GWAS [53] and thus may also be contributing to the nominal main effects we observed. The relationship between blood azelaic acid and cognitive function is inconsistent [54,55] while urinary azelaic acid is generally elevated in participants with AD, major depressive or bipolar disorders, compared to controls [56,57]. Conversely, uric acid levels are inversely associated with AD and Parkinson’s disease with dementia [58] and would be more consistent with our genetic findings. The main effects of COMT and SLC17A1 variation on cognition over time may be plausible, but we acknowledge that neither variant associates with cognitive decline or dementia in GWAS. Moreover, we cannot discount a possible interaction with weight loss, observed in both diet assignments over time.
Genetic variation in vitamin K, vitamin E, beta carotene, alpha-carotene, folate, oleic acid, and iron metabolic pathways did not modify cognitive response to MIND over time. Diet interactions with genetic variation in BMI and IR were also non-significant, though participant selection criteria (overweight) may have biased results. Our hypothesis testing was limited by knowledge of biomarkers for MIND-diet intake and corresponding genetic loci identified in European populations. GS had a variable number of SNPs with variable effect sizes, likely contributing to differential power to detect interactions. A genome-wide interaction analysis of the MIND diet on cognitive change was also performed as an exploratory analysis and to provide a data resource for other nutrition or genetic investigators. While we identified genome-wide significant SNP-diet interactions, these were driven by low-frequency variants and may be false positives. We have made all summary statistics for this exploratory analysis publicly accessible for replication or follow-up analysis.
The use of a large, well-designed RCT with excellent adherence for a comprehensive genetic analysis of cognitive response to the MIND diet is a major strength of the current study. However, unlike population-based genetic analysis of MIND adherence and cognitive function, the sample size provides limited power, especially for discovery. Our study was also limited to highly adherent participants of European Ancestry with an elevated risk of dementia.

5. Conclusions

In summary, we observed an interaction between the COMT Val158Met variant and diet assignment for the 3-year change in perceptual speed. Individuals with genetically impaired COMT activity may be especially responsive to the cognitive benefits of the MIND diet. Reduced perceptual speed in older adults is an early and sensitive indicator of broader cognitive decline and loss of independence in daily living activities [59,60]. While the original RCT did not report significant overall differences in cognitive change after 3 years of consuming a MIND diet compared to the control diet, our genetic analysis suggests potential response heterogeneity that warrants confirmation.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu18030508/s1. Table S1. MIND diet. Table S2. Candidate nutrient and biomarker loci. Table S3. Cognitive domains and tests used in the MIND Trial. Table S4. Late-Onset Alzheimer’s Disease Risk Loci. Table S5. Nominal associations (0.004 < p < 0.05) between genetic scores (GS) and baseline cognitive performance. Table S6. Estimated mean change (95% CI) in executive function from baseline by GSazelaic and GSCOMT. Table S7. Estimated mean change (95% CI) in perceptual speed from baseline by diet assignment and GSCOMT. Table S8. Genome-wide SNP×diet interactions and change in cognitive function after 3 years. Table S9. Estimated mean change (SD) in cognitive scores at 3 years from baseline stratified by genotype and diet assignment. Figure S1. GSazelaic (SLC17A1, rs1165213) and change in executive function. Figure S2. GSCOMT (rs4680) and change in urinary tyrosol by diet assignment. Figure S3. Manhattan plots for genome-wide association analysis of change in global cognition score. Figure S4. Manhattan plots for genome-wide association analysis of change in executive function score. Figure S5. Manhattan plots for genome-wide association analysis of change in semantic memory score. Figure S6. Manhattan plots for genome-wide association analysis of change in perceptual speed score. References [61,62,63,64,65,66,67,68] are cited in the Supplementary Materials

Author Contributions

Conceptualization: M.C.C.; methodology: M.C.C.; formal analysis: M.C.C.; investigation: M.C.C.; resources: M.C.C. and L.L.B.; data curation: M.C.C.; writing—original draft preparation: M.C.C.; writing—review and editing: M.C.C. and L.L.B.; supervision: M.C.C.; project administration: L.L.B. and M.C.C.; funding acquisition: M.C.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Institute on Aging (NIA, R01AG065398). Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the NIA.

Institutional Review Board Statement

The current study is a secondary analysis of the MIND trial. The trial followed the ethical standards of the 1964 Declaration of Helsinki and its later amendments and was approved by the institutional review boards at Rush University Medical Center, Harvard School of Public Health, and Brigham and Women’s Hospital (protocol code 15052004-IRB01, approved on 23 November 2017).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Genetic data will be made available via NIAGADS, https://dss.niagads.org/, in accordance with NIH/NIA guidelines for genetic resource sharing. MIND trial phenotyping can be accessed upon approval at https://www.radc.rush.edu. Summary statistics are available at https://prism.northwestern.edu/.

Acknowledgments

All analyses were run on the Quest cluster, supported in part through the computational resources and staff contributions provided for the Quest high-performance computing facility at Northwestern University, which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. We thank the participants from the MIND trial and acknowledge Martha Clare Morris, a pioneer in nutrition–dementia research, who conceived the MIND trial but unfortunately passed before the MIND trial was complete.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Morris, M.C.; Tangney, C.C.; Wang, Y.; Sacks, F.M.; Barnes, L.L.; Bennett, D.A.; Aggarwal, N.T. MIND diet slows cognitive decline with aging. Alzheimers Dement. 2015, 11, 1015–1022. [Google Scholar] [CrossRef] [Scilit]
  2. Morris, M.C. Nutritional determinants of cognitive aging and dementia. Proc. Nutr. Soc. 2012, 71, 1–13. [Google Scholar] [CrossRef] [Scilit]
  3. van Soest, A.P.M.; Beers, S.; van de Rest, O.; de Groot, L.C. The Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) Diet for the Aging Brain: A Systematic Review. Adv. Nutr. 2024, 15, 100184. [Google Scholar] [CrossRef] [Scilit]
  4. Barnes, L.L.; Dhana, K.; Liu, X.; Carey, V.J.; Ventrelle, J.; Johnson, K.; Hollings, C.S.; Bishop, L.; Laranjo, N.; Stubbs, B.J.; et al. Trial of the MIND Diet for Prevention of Cognitive Decline in Older Persons. N. Engl. J. Med. 2023, 389, 602–611. [Google Scholar] [CrossRef] [Scilit]
  5. Arjmand, G.; Abbas-Zadeh, M.; Eftekhari, M.H. Effect of MIND diet intervention on cognitive performance and brain structure in healthy obese women: A randomized controlled trial. Sci. Rep. 2022, 12, 2871. [Google Scholar] [CrossRef] [Scilit]
  6. Elsayed, M.M.; Rabiee, A.; El Refaye, G.E.; Elsisi, H.F. Aerobic Exercise with Mediterranean-DASH Intervention for Neurodegenerative Delay Diet Promotes Brain Cells’ Longevity despite Sex Hormone Deficiency in Postmenopausal Women: A Randomized Controlled Trial. Oxid. Med. Cell. Longev. 2022, 2022, 4146742. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. van de Rest, O.; Wang, Y.; Barnes, L.L.; Tangney, C.; Bennett, D.A.; Morris, M.C. APOE epsilon4 and the associations of seafood and long-chain omega-3 fatty acids with cognitive decline. Neurology 2016, 86, 2063–2070. [Google Scholar] [CrossRef] [Scilit]
  8. Cornelis, M.C.; Agarwal, P.; Holland, T.M.; van Dam, R.M. MIND Dietary Pattern and Its Association with Cognition and Incident Dementia in the UK Biobank. Nutrients 2022, 15, 32. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Vu, T.H.T.; Beck, T.; Bennett, D.A.; Schneider, J.A.; Hayden, K.M.; Shadyab, A.H.; Rajan, K.B.; Morris, M.C.; Cornelis, M.C. Adherence to MIND Diet, Genetic Susceptibility, and Incident Dementia in Three US Cohorts. Nutrients 2022, 14, 2759. [Google Scholar] [CrossRef] [Scilit]
  10. Migliore, L.; Coppedè, F. Gene–environment interactions in Alzheimer disease: The emerging role of epigenetics. Nat. Rev. Neurol. 2022, 18, 643–660. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Olsson, E.; Karlström, B.; Kilander, L.; Byberg, L.; Cederholm, T.; Sjögren, P. Dietary patterns and cognitive dysfunction in a 12-year follow-up study of 70 year old men. J. Alzheimers Dis. 2015, 43, 109–119. [Google Scholar] [CrossRef] [Scilit]
  12. Duplantier, S.C.; Gardner, C.D. A Critical Review of the Study of Neuroprotective Diets to Reduce Cognitive Decline. Nutrients 2021, 13, 2264. [Google Scholar] [CrossRef] [Scilit]
  13. Bischof, G.N.; Park, D.C. Obesity and aging: Consequences for cognition, brain structure, and brain function. Psychosom. Med. 2015, 77, 697–709. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Dahl, A.; Hassing, L.B.; Fransson, E.; Berg, S.; Gatz, M.; Reynolds, C.A.; Pedersen, N.L. Being Overweight in Midlife Is Associated with Lower Cognitive Ability and Steeper Cognitive Decline in Late Life. J. Gerontol. A Biol. Sci. Med. Sci. 2009, 65A, 57–62. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Gómez-Apo, E.; Mondragón-Maya, A.; Ferrari-Díaz, M.; Silva-Pereyra, J. Structural Brain Changes Associated with Overweight and Obesity. J. Obes. 2021, 2021, 6613385. [Google Scholar] [CrossRef] [Scilit]
  16. Opel, N.; Thalamuthu, A.; Milaneschi, Y.; Grotegerd, D.; Flint, C.; Leenings, R.; Goltermann, J.; Richter, M.; Hahn, T.; Woditsch, G.; et al. Brain structural abnormalities in obesity: Relation to age, genetic risk, and common psychiatric disorders. Mol. Psychiatry 2021, 26, 4839–4852. [Google Scholar] [CrossRef] [Scilit]
  17. Liu, X.; Morris, M.C.; Dhana, K.; Ventrelle, J.; Johnson, K.; Bishop, L.; Hollings, C.S.; Boulin, A.; Laranjo, N.; Stubbs, B.J.; et al. Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) study: Rationale, design and baseline characteristics of a randomized control trial of the MIND diet on cognitive decline. Contemp. Clin. Trials 2021, 102, 106270. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Liu, Y.; Fowler, H.; Wang, D.D.; Barnes, L.L.; Cornelis, M.C. Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Trial: Genetic Resource for Precision Nutrition. Nutrients 2025, 17, 2548. [Google Scholar] [CrossRef] [Scilit]
  19. Lambert, J.C.; Ibrahim-Verbaas, C.A.; Harold, D.; Naj, A.C.; Sims, R.; Bellenguez, C.; Jun, G.; Destefano, A.L.; Bis, J.C.; Beecham, G.W.; et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat. Genet. 2013, 45, 1452–1458. [Google Scholar] [CrossRef] [Scilit]
  20. Jansen, I.; Savage, J.; Watanabe, K.; Bryois, J.; Williams, D.; Steinberg, S.; Sealock, J.; Karlsson, I.; Hägg, S.; Athanasiu, L. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat. Genet. 2019, 51, 404–413. [Google Scholar] [CrossRef] [Scilit]
  21. Locke, A.E.; Kahali, B.; Berndt, S.I.; Justice, A.E.; Pers, T.H.; Day, F.R.; Powell, C.; Vedantam, S.; Buchkovich, M.L.; Yang, J.; et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015, 518, 197–206. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Chen, J.; Spracklen, C.N.; Marenne, G.; Varshney, A.; Corbin, L.J.; Luan, J.; Willems, S.M.; Wu, Y.; Zhang, X.; Horikoshi, M.; et al. The trans-ancestral genomic architecture of glycemic traits. Nat. Genet. 2021, 53, 840–860. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Miró-Casas, E.; Farré Albaladejo, M.; Covas, M.I.; Rodriguez, J.O.; Menoyo Colomer, E.; Lamuela Raventós, R.M.; de la Torre, R. Capillary gas chromatography-mass spectrometry quantitative determination of hydroxytyrosol and tyrosol in human urine after olive oil intake. Anal. Biochem. 2001, 294, 63–72. [Google Scholar] [CrossRef] [Scilit]
  24. Auger, C.; Al-Awwadi, N.; Bornet, A.; Rouanet, J.-M.; Gasc, F.; Cros, G.; Teissedre, P.-L. Catechins and procyanidins in Mediterranean diets. Food Res. Int. 2004, 37, 233–245. [Google Scholar] [CrossRef] [Scilit]
  25. Most, M.M. Estimated phytochemical content of the Dietary Approaches to Stop Hypertension (DASH) diet is higher than in the control study diet. J. Am. Diet. Assoc. 2004, 104, 1725–1727. [Google Scholar] [CrossRef] [Scilit]
  26. Mattioli, R.; Francioso, A.; Mosca, L.; Silva, P. Anthocyanins: A Comprehensive Review of Their Chemical Properties and Health Effects on Cardiovascular and Neurodegenerative Diseases. Molecules 2020, 25, 3809. [Google Scholar] [CrossRef] [Scilit]
  27. Micheli, L.; Bertini, L.; Bonato, A.; Villanova, N.; Caruso, C.; Caruso, M.; Bernini, R.; Tirone, F. Role of Hydroxytyrosol and Oleuropein in the Prevention of Aging and Related Disorders: Focus on Neurodegeneration, Skeletal Muscle Dysfunction and Gut Microbiota. Nutrients 2023, 15, 1767. [Google Scholar] [CrossRef] [Scilit]
  28. Zaa, C.A.; Marcelo, Á.J.; An, Z.; Medina-Franco, J.L.; Velasco-Velázquez, M.A. Anthocyanins: Molecular Aspects on Their Neuroprotective Activity. Biomolecules 2023, 13, 1598. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Zhu, B. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: Importance in pathophysiology and pathogenesis. Curr. Drug Metab. 2002, 3, 321–349. [Google Scholar] [CrossRef] [Scilit]
  30. Tunbridge, E.M. The catechol-O-methyltransferase gene: Its regulation and polymorphisms. Int. Rev. Neurobiol. 2010, 95, 7–27. [Google Scholar] [CrossRef] [Scilit]
  31. Lotta, T.; Vidgren, J.; Tilgmann, C.; Ulmanen, I.; Melen, K.; Julkunen, I.; Taskinen, J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34, 4202–4210. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. He, B.; Shi, J.; Wang, X.; Jiang, H.; Zhu, H.J. Genome-wide pQTL analysis of protein expression regulatory networks in the human liver. BMC Biol. 2020, 18, 97. [Google Scholar] [CrossRef] [Scilit]
  33. Chen, J.; Lipska, B.K.; Halim, N.; Ma, Q.D.; Matsumoto, M.; Melhem, S.; Kolachana, B.S.; Hyde, T.M.; Herman, M.M.; Apud, J. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75, 807–821. [Google Scholar] [CrossRef] [Scilit]
  34. Papenberg, G.; Lindenberger, U.; Bäckman, L. Aging-related magnification of genetic effects on cognitive and brain integrity. Trends Cogn. Sci. 2015, 19, 506–514. [Google Scholar] [CrossRef] [Scilit]
  35. Scheggia, D.; Sannino, S.; Luisa Scattoni, M.; Papaleo, F. COMT as a drug target for cognitive functions and dysfunctions. CNS Neurol. Disord. Drug Targets 2012, 11, 209–221. [Google Scholar] [CrossRef] [Scilit]
  36. Tunbridge, E.M.; Harrison, P.J.; Weinberger, D.R. Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond. Biol. Psychiatry 2006, 60, 141–151. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Arnsten, A.F.; Li, B.-M. Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 2005, 57, 1377–1384. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. Witte, A.V.; Jansen, S.; Schirmacher, A.; Young, P.; Flöel, A. COMT Val158Met Polymorphism Modulates Cognitive Effects of Dietary Intervention. Front. Aging Neurosci. 2010, 2, 146. [Google Scholar] [CrossRef] [Scilit]
  39. Gui, H.; Sun, L.; Liu, R.; Si, X.; Li, D.; Wang, Y.; Shu, C.; Sun, X.; Jiang, Q.; Qiao, Y.; et al. Current knowledge of anthocyanin metabolism in the digestive tract: Absorption, distribution, degradation, and interconversion. Crit. Rev. Food Sci. Nutr. 2023, 63, 5953–5966. [Google Scholar] [CrossRef] [Scilit]
  40. Landis-Piwowar, K.; Chen, D.; Chan, T.H.; Dou, Q.P. Inhibition of catechol-O-methyltransferase activity in human breast cancer cells enhances the biological effect of the green tea polyphenol (-)-EGCG. Oncol. Rep. 2010, 24, 563–569. [Google Scholar] [CrossRef] [Scilit]
  41. De la Torre, R.; Corella, D.; Castañer, O.; Martínez-González, M.A.; Salas-Salvador, J.; Vila, J.; Estruch, R.; Sorli, J.V.; Arós, F.; Fiol, M.; et al. Protective effect of homovanillyl alcohol on cardiovascular disease and total mortality: Virgin olive oil, wine, and catechol-methylathion1, 2, 3. Am. J. Clin. Nutr. 2017, 105, 1297–1304. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Visioli, F.; Davalos, A.; López de las Hazas, M.-C.; Crespo, M.C.; Tomé-Carneiro, J. An overview of the pharmacology of olive oil and its active ingredients. Br. J. Pharmacol. 2020, 177, 1316–1330. [Google Scholar] [CrossRef] [Scilit]
  43. Serreli, G.; Deiana, M. Biological Relevance of Extra Virgin Olive Oil Polyphenols Metabolites. Antioxidants 2018, 7, 170. [Google Scholar] [CrossRef] [Scilit]
  44. Karković Marković, A.; Torić, J.; Barbarić, M.; Jakobušić Brala, C. Hydroxytyrosol, Tyrosol and Derivatives and Their Potential Effects on Human Health. Molecules 2019, 24, 2001. [Google Scholar] [CrossRef] [Scilit]
  45. Boronat, A.; Mateus, J.; Soldevila-Domenech, N.; Guerra, M.; Rodríguez-Morató, J.; Varon, C.; Muñoz, D.; Barbosa, F.; Morales, J.C.; Gaedigk, A. Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial. Free Radic. Biol. Med. 2019, 143, 471–481. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Zhu, K.; Li, R.; Yao, P.; Yu, H.; Pan, A.; Manson, J.E.; Rimm, E.B.; Willett, W.C.; Liu, G. Proteomic signatures of healthy dietary patterns are associated with lower risks of major chronic diseases and mortality. Nat. Food 2025, 6, 47–57. [Google Scholar] [CrossRef] [Scilit]
  47. Gonzalez-Dominguez, R.; Jauregui, O.; Queipo-Ortuno, M.I.; Andres-Lacueva, C. Characterization of the Human Exposome by a Comprehensive and Quantitative Large-Scale Multianalyte Metabolomics Platform. Anal. Chem. 2020, 92, 13767–13775. [Google Scholar] [CrossRef] [Scilit]
  48. Renai, L.; Ancillotti, C.; Ulaszewska, M.; Garcia-Aloy, M.; Mattivi, F.; Bartoletti, R.; Del Bubba, M. Comparison of chemometric strategies for potential exposure marker discovery and false-positive reduction in untargeted metabolomics: Application to the serum analysis by LC-HRMS after intake of Vaccinium fruit supplements. Anal. Bioanal. Chem. 2022, 414, 1841–1855. [Google Scholar] [CrossRef] [Scilit]
  49. Bondia-Pons, I.; Barri, T.; Hanhineva, K.; Juntunen, K.; Dragsted, L.O.; Mykkänen, H.; Poutanen, K. UPLC-QTOF/MS metabolic profiling unveils urinary changes in humans after a whole grain rye versus refined wheat bread intervention. Mol. Nutr. Food Res. 2013, 57, 412–422. [Google Scholar] [CrossRef] [Scilit]
  50. Petrovici, A.-G.; Spennato, M.; Bîtcan, I.; Péter, F.; Cotarcă, L.; Todea, A.; Ordodi, V.L. A Comprehensive Review of Azelaic Acid Pharmacological Properties, Clinical Applications, and Innovative Topical Formulations. Pharmaceuticals 2025, 18, 1273. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Schlosser, P.; Scherer, N.; Grundner-Culemann, F.; Monteiro-Martins, S.; Haug, S.; Steinbrenner, I.; Uluvar, B.; Wuttke, M.; Cheng, Y.; Ekici, A.B.; et al. Genetic studies of paired metabolomes reveal enzymatic and transport processes at the interface of plasma and urine. Nat. Genet. 2023, 55, 995–1008. [Google Scholar] [CrossRef] [Scilit]
  52. Reimer, R.J. SLC17: A functionally diverse family of organic anion transporters. Mol. Asp. Med. 2013, 34, 350–359. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Boocock, J.; Leask, M.; Okada, Y.; Matsuo, H.; Kawamura, Y.; Shi, Y.; Li, C.; Mount, D.B.; Mandal, A.K.; Wang, W.; et al. Genomic dissection of 43 serum urate-associated loci provides multiple insights into molecular mechanisms of urate control. Hum. Mol. Genet. 2020, 29, 923–943. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Zhou, Y.; Zhou, K.; Lin, X.; Wei, Y.; Ma, B.; Lu, S.; Xie, G.; Zhang, Z.; Liang, J. Association of gut microbiota, plasma and fecal metabolite profiles with intellectual development in school-age children. Transl. Pediatr. 2023, 12, 1292–1304. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Gordon, S.; Lee, J.S.; Scott, T.M.; Bhupathiraju, S.; Ordovas, J.; Kelly, R.S.; Tucker, K.L.; Palacios, N. Metabolites and Cognitive Decline in a Puerto Rican Cohort. J. Alzheimers Dis. 2024, 99, S345–S353. [Google Scholar] [CrossRef] [Scilit]
  56. An, M.; Gao, Y. Urinary Biomarkers of Brain Diseases. Genom. Proteom. Bioinform. 2015, 13, 345–354. [Google Scholar] [CrossRef] [Scilit]
  57. Castor, K.J.; Shenoi, S.; Edminster, S.P.; Tran, T.; King, K.S.; Chui, H.; Pogoda, J.M.; Fonteh, A.N.; Harrington, M.G. Urine dicarboxylic acids change in pre-symptomatic Alzheimer’s disease and reflect loss of energy capacity and hippocampal volume. PLoS ONE 2020, 15, e0231765. [Google Scholar] [CrossRef] [Scilit]
  58. Zhou, Z.; Zhong, S.; Liang, Y.; Zhang, X.; Zhang, R.; Kang, K.; Qu, H.; Xu, Y.; Zhao, C.; Zhao, M. Serum uric acid and the risk of dementia: A systematic review and meta-analysis. Front. Aging Neurosci. 2021, 13, 625690. [Google Scholar] [CrossRef] [Scilit]
  59. Vance, D.; Heaton, K.; Fazeli, P.; Ackerman, M. Aging, Speed of Processing Training, and Everyday Functioning: Implications for Practice and Research. Act. Adapt. Aging 2010, 34, 276–291. [Google Scholar] [CrossRef] [Scilit]
  60. Salthouse, T.A. The processing-speed theory of adult age differences in cognition. Psychol. Rev. 1996, 103, 403. [Google Scholar] [CrossRef] [Scilit]
  61. D’Adamo, C.R.; Dawson, V.J.; Ryan, K.A.; Yerges-Armstrong, L.M.; Semba, R.D.; Steinle, N.I.; Mitchell, B.D.; Shuldiner, A.R.; McArdle, P.F. The CAPN2/CAPN8 Locus on Chromosome 1q Is Associated with Variation in Serum Alpha-Carotene Concentrations. J. Nutr. Nutr. 2016, 9, 254–264. [Google Scholar] [CrossRef] [Scilit]
  62. Wood, A.R.; Perry, J.R.; Tanaka, T.; Hernandez, D.G.; Zheng, H.F.; Melzer, D.; Gibbs, J.R.; Nalls, M.A.; Weedon, M.N.; Spector, T.D.; et al. Imputation of variants from the 1000 Genomes Project modestly improves known associations and can identify low-frequency variant-phenotype associations undetected by HapMap based imputation. PLoS ONE 2013, 8, e64343. [Google Scholar] [CrossRef] [Scilit]
  63. Major, J.M.; Yu, K.; Wheeler, W.; Zhang, H.; Cornelis, M.C.; Wright, M.E.; Yeager, M.; Snyder, K.; Weinstein, S.J.; Mondul, A.; et al. Genome-wide association study identifies common variants associated with circulating vitamin E levels. Hum. Mol. Genet. 2011, 20, 3876–3883. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Surendran, P.; Stewart, I.D.; Au Yeung, V.P.W.; Pietzner, M.; Raffler, J.; Worheide, M.A.; Li, C.; Smith, R.F.; Wittemans, L.B.L.; Bomba, L.; et al. Rare and common genetic determinants of metabolic individuality and their effects on human health. Nat. Med. 2022, 28, 2321–2332. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Grarup, N.; Sulem, P.; Sandholt, C.H.; Thorleifsson, G.; Ahluwalia, T.S.; Steinthorsdottir, V.; Bjarnason, H.; Gudbjartsson, D.F.; Magnusson, O.T.; Sparso, T.; et al. Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets. PLoS Genet. 2013, 9, e1003530. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Dashti, H.S.; Shea, M.K.; Smith, C.E.; Tanaka, T.; Hruby, A.; Richardson, K.; Wang, T.J.; Nalls, M.A.; Guo, X.; Liu, Y.; et al. Meta-analysis of genome-wide association studies for circulating phylloquinone concentrations. Am. J. Clin. Nutr. 2014, 100, 1462–1469. [Google Scholar] [CrossRef] [Scilit]
  67. Hu, Y.; Tanaka, T.; Zhu, J.; Guan, W.; Wu, J.H.Y.; Psaty, B.M.; McKnight, B.; King, I.B.; Sun, Q.; Richard, M.; et al. Discovery and fine-mapping of loci associated with MUFAs through trans-ethnic meta-analysis in Chinese and European populations. J. Lipid Res. 2017, 58, 974–981. [Google Scholar] [CrossRef] [Scilit]
  68. Cornelis, M.C.; Fazlollahi, A.; Bennett, D.A.; Schneider, J.A.; Ayton, S. Genetic Markers of Postmortem Brain Iron. J. Neurochem. 2025, 169, e16309. [Google Scholar] [CrossRef] [Scilit]
Nutrients 18 00508 g001
Figure 1. GSCOMT (rs4680) and change in executive function. Shown are the estimated means of executive function score by genotype from linear mixed models (p = 0.02).
Figure 1. GSCOMT (rs4680) and change in executive function. Shown are the estimated means of executive function score by genotype from linear mixed models (p = 0.02).
Nutrients 18 00508 g001
Nutrients 18 00508 g002
Figure 2. (A,B) GSCOMT (rs4680) and change in perceptual speed by diet assignment. Shown are estimated means of perceptual speed score by genotype and diet assignment from linear mixed models (p = 0.002 for interaction).
Figure 2. (A,B) GSCOMT (rs4680) and change in perceptual speed by diet assignment. Shown are estimated means of perceptual speed score by genotype and diet assignment from linear mixed models (p = 0.002 for interaction).
Nutrients 18 00508 g002
Table 1. Baseline characteristics of MIND trial participants *.
Table 1. Baseline characteristics of MIND trial participants *.
CharacteristicCurrent SampleFull Trial Sample
MINDControlMINDControl
N = 249N = 245N = 301N = 303
Age at randomization, years69.8 (4.2)70.1 (4.3)69.8 (4.2)69.9 (4.2)
Male, %37363535
At least a college degree, %78817680
BMI33.6 (5.3)33.6 (5.9)33.8 (5.4)34.0 (6.5)
Race, %
White1001008788
Black001210
Other0012
Current smoker, %3233
Diabetes, %14131515
MIND score7.6 (1.9)7.8 (1.8)7.7 (1.9)7.8 (1.8)
Study Site, %
Rush47495050
Harvard53515050
APOE ε4-carrier, %24322532
* MIND trial participants for the current analysis vs. all MIND trial participants. Data are means (SD) unless otherwise specified.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Cornelis, M.C.; Barnes, L.L. Genetic Variation in Response to the Mediterranean–DASH Intervention for Neurodegenerative Delay (MIND): A Randomized Controlled Trial. Nutrients 2026, 18, 508. https://doi.org/10.3390/nu18030508

AMA Style

Cornelis MC, Barnes LL. Genetic Variation in Response to the Mediterranean–DASH Intervention for Neurodegenerative Delay (MIND): A Randomized Controlled Trial. Nutrients. 2026; 18(3):508. https://doi.org/10.3390/nu18030508

Chicago/Turabian Style

Cornelis, Marilyn C., and Lisa L. Barnes. 2026. "Genetic Variation in Response to the Mediterranean–DASH Intervention for Neurodegenerative Delay (MIND): A Randomized Controlled Trial" Nutrients 18, no. 3: 508. https://doi.org/10.3390/nu18030508

APA Style

Cornelis, M. C., & Barnes, L. L. (2026). Genetic Variation in Response to the Mediterranean–DASH Intervention for Neurodegenerative Delay (MIND): A Randomized Controlled Trial. Nutrients, 18(3), 508. https://doi.org/10.3390/nu18030508

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop